

1

2 Wastewater sequencing from a rural community enables identification of
3 widespread adaptive mutations in a SARS-CoV-2 Alpha variant

4 Michael J. Conway^{1,5*}, Michael P. Novay¹, Carson M. Pusch¹, Avery S. Ward¹, Jackson
5 D. Abel¹, Maggie R. Williams^{4,5}, Rebecca L. Uzarski³, and Elizabeth W. Alm^{2,5}

6 *¹Foundational Sciences, Central Michigan University*
7 *College of Medicine, Mt. Pleasant, MI, USA*

8 *²Department of Biology, Central Michigan University,*
9 *Mt. Pleasant, MI, USA*

10 *³Department of Biology and Herbert H. and Grace A. Dow College of Health*
11 *Professions, Central Michigan University, Mt. Pleasant MI, USA*

12 *⁴School of Engineering & Technology, Central Michigan University,*
13 *Mt. Pleasant, MI, USA*

14 *⁵Institute for Great Lakes Research, Central Michigan University,*
15 *Mt. Pleasant, MI, USA*

16
17

18 # Address correspondence to: Foundational Sciences, Central Michigan University
19 College of Medicine, Mount Pleasant, MI, 48859

20 E-mail: michael.conway@cmich.edu. Phone: (989) 774-3930, Fax: (989) 774-3462

21
22
23
24

Short title: Complete Alpha Reconstruction

25
26

27 **Abstract**

28

29 **Background:** Central Michigan University (CMU) participated in a state-wide
30 wastewater monitoring program starting in 2021. One rural site consistently produced
31 higher concentrations of SARS-CoV-2 genome copies. Samples from this site were
32 sequenced retrospectively and exclusively contained a derivative of Alpha variant lineage
33 B.1.1.7 that shed from the same site for 20-28 months.

34 **Results:** Complete reconstruction of each SARS-CoV-2 open reading frame (ORF) and
35 alignment to an early B.1.1.7 clinical isolate identified novel mutations that were selected
36 in non-structural (nsp1, nsp2, nsp3, nsp4, nsp5/3CLpro, nsp6, RdRp, nsp15, nsp16,
37 ORF3a, ORF6, ORF7a, and ORF7b) and structural genes (Spike, M, and N). These were
38 rare mutations that have not accumulated in clinical samples worldwide. Mutational
39 analysis revealed divergence from the reference Alpha variant lineage sequence over
40 time. We present each of the mutations on available structural models and discuss the
41 potential role of these mutations during a chronic infection.

42 **Conclusions:** This study further supports that small wastewater treatment plants can
43 enhance resolution of rare events and facilitate reconstruction of viral genomes due to the
44 relative lack of contaminating sequences and identifies mutations that may be associated
45 with chronic infections.

46

47

48

49

50 **Declarations**

51 **-Ethics approval and consent to participate**

52 **Not applicable**

53 **-Consent for publication***

54 **Not applicable**

55 **-Availability of data and materials**

56 **FASTQ files for each sample are available in the NCBI SRA database (Submission**
57 **ID: SUB13897431; BioProject ID: PRJNA1027333).**

58 **-Competing interests**

59 **The authors have no competing interests.**

60 **-Funding**

61 **Michigan Department of Health and Human Services (MDHHS)**

62 **-Authors' contributions**

63 **MJC wrote the manuscript and directed the wastewater monitoring activities, MPN**
64 **reconstructed ORFs, CMP analyzed FASTQ data and developed the heatmap, ASW**
65 **and JDA performed all wastewater monitoring activities including submission of**
66 **samples for NGS, MRW supported data analysis and submission to the health**
67 **department and manuscript revision, RLU served as a liaison between wastewater**
68 **treatment plants and student research assistants, and EWA assisted in data analysis**
69 **and manuscript revision.**

70 **-Acknowledgements**

71 **We thank MDHHS and MiNET for supporting wastewater collection,**
72 **processing, and data analysis. We also thank the WWTP staff who provided**

73 **samples every week during a pandemic. We thank CMU undergraduate assistants**
74 **Justus Holben, Gabrielle Reau, Jessica Broach, Hamzah Khan, Jayde-Ann Taylor,**
75 **Ashley Bergmooser, Kaitlyn Perry, Emily Rosema, Alexis Bruce, and Lauren**
76 **Revord for their support. This is contribution number XXX of the Central**
77 **Michigan University Institute for Great Lakes Research.**

78

79 **1. Introduction**

80 Wastewater monitoring has become a firmly established public health tool since
81 the COVID-19 pandemic. Wastewater monitoring programs have helped identify
82 potential outbreaks within communities and individual buildings, they can track variants
83 of concern, and they are being leveraged for new emerging infectious diseases (1-12).
84 The goal of wastewater monitoring is to provide complementary data to public health
85 agencies so that they can make informed decisions to mitigate infectious disease
86 transmission.

87

88 The State of Michigan Department of Health and Human Services (MDHHS)
89 initiated a wastewater monitoring program in 2021. The program included partnerships
90 between academic laboratories and regional public health departments that spanned large
91 and small metropolitan areas and rural areas in both lower and upper peninsulas. Central
92 Michigan University (CMU) formed a partnership with the Central Michigan District
93 Health Department (CMDHD). This partnership provided an opportunity to look at the
94 dynamics of SARS-CoV-2 at a regional public university and in the surrounding small

95 metropolitan and rural communities (13). We identified ten on-campus sewer sites and
96 nine off-campus wastewater treatment plants (WWTPs) to sample on a weekly basis.

97

98 Sampling began in July 2021, which was at least seven months after emergence of
99 the Alpha variant (B.1.1.7) in Michigan. The Alpha variant first appeared in North
100 America in late November 2020 and became the predominant SARS-CoV-2 variant by
101 the end of March 2021 (14). It became clear that our smallest WWTP (estimated
102 population served: 851) consistently produced higher concentrations of SARS-CoV-2
103 genome copies. Samples taken from this site from 2021-2023 were retrospectively
104 sequenced and many contained sequences that corresponded to an Alpha variant lineage
105 B.1.1.7. We reconstructed the Spike gene and identified 37 mutations that accumulated in
106 the RBD and NTD (15). Here, we use the same set of data to provide a complete
107 reconstruction of each SARS-CoV-2 open reading frame (ORF). Alignment of each ORF
108 to an early B.1.1.7 clinical isolate identified novel mutations that were selected in non-
109 structural (nsp1, nsp2, nsp3, nsp4, nsp5/3CLpro, nsp6, RdRp, nsp15, nsp16, ORF3a,
110 ORF6, ORF7a, and ORF7b) and structural genes (Spike, M, and N). Each of these
111 mutations were present in less than 2% of clinical samples present in GenBank and the
112 sequence read archive (SRA) from Dec 2023 to Jun 2024. These were rare mutations, yet
113 three were previously associated with immunodeficiency, adaptation to remdesivir, and
114 reinfection of a hospital worker (16-20). Temporal mutational analysis revealed
115 divergence from the reference Alpha variant lineage sequence over time. Each mutation
116 was mapped onto available structural models, and we discuss the potential significance of
117 these changes during a chronic SARS-CoV-2 infection.

118

119 This manuscript provides further support that wastewater monitoring in small
120 metropolitan and rural communities is an opportunity to identify novel variants and
121 reconstruct whole genomes due to lower contamination with unrelated sequences. It is
122 important to note that the reconstruction strategy that was used will incorporate
123 contaminating variant sequences if they are present. These data also support that humans
124 can chronically shed SARS-CoV-2 for close to two years. Considering the low
125 prevalence of these mutations in clinical samples, chronic shedding of SARS-CoV-2 is
126 likely a rare event that leads to accumulation of adaptive mutations. Identifying mutations
127 associated with chronic infection may be useful to diagnose individuals who have
128 persistent disease and to assist in the selection of appropriate treatment.

129

130 **2. Materials and methods**

131

132 **2.1. Selection of sample sites**

133 Central Michigan University (CMU) is a public research university in the City of
134 Mt. Pleasant, Isabella County, Michigan, with an average population during the 2021-
135 2022 academic year of 13,684 students and staff. Ten sample sites were selected on
136 campus that collected wastewater downstream from most campus buildings, including
137 residential halls, apartments, and academic/administrative buildings. The waste stream at
138 these sites includes a mixture of wastewater from CMU and upstream residential areas in
139 the City of Mt. Pleasant. Nine off-campus sites throughout the jurisdictions of the Central
140 Michigan District Health Department (CMDHD) and Mid-Michigan District Health

141 Department (MMDHD) were selected (13), which included the City of Mt. Pleasant,
142 Union Township, City of Alma, City of Clare, City of Ewart, three Houghton Lake
143 townships, and Village of Marion wastewater treatment plants (WWTPs). These locations
144 represent various land uses and population densities including urban, rural, and suburban
145 areas, providing a large footprint of SARS CoV-2 virus shedding in Central Michigan.

146

147 **2.2. Wastewater collection**

148 Since July 2021, wastewater samples (500–1000 mL) were collected once each
149 week on either Monday or Tuesday from ten sanitary sewer sites and nine WWTP
150 influent streams (after grit removal). Sanitary sewer grab samples consisted of
151 wastewater flowing from university dormitories and buildings and the surrounding
152 community. Influent to WWTPs were collected as grab samples or 24-hour composite
153 samples. Samples were held at 4°C no more than 48 hours before analysis (13).

154

155 **2.3. Virus concentration and RNA extraction**

156 The protocol described by Flood et al. 2021 and adopted by the Michigan
157 wastewater monitoring network was used to concentrate virus from samples and extract
158 viral RNA (13, 53). Briefly, 100 mL wastewater or water as a negative control was mixed
159 with 8% (w/v) molecular biology grade PEG 8000 (Promega Corporation, Madison WI)
160 and 0.2 M NaCl (w/v). The sample was mixed slowly on a magnetic stirrer at 4 °C for 2-
161 16 hours. Following overnight incubation, samples were centrifuged at 4,700×g for 45
162 min at 4 °C. The supernatant was then removed, and the pellet was resuspended in the
163 remaining liquid, which ranged from 1-3 mL. All sample concentrates were aliquoted and

164 stored at -80 °C until further processing. Viral RNA was extracted from concentrated
165 wastewater using the Qiagen QIAmp Viral RNA Minikit according to the manufacturer's
166 protocol with previously published modifications (Qiagen, Germany) (53). In this study,
167 a total of 200 µl of concentrate was used for RNA extraction resulting in a final elution
168 volume of 80 µl. Extracted RNA was stored at -80 °C until analysis. A wastewater
169 negative extraction control was included. To derive recovery efficiencies for each sample
170 site, samples were inoculated with 10⁶ gene copies (GC)/mL Phi6 bacteriophage (Phi6)
171 prior to the addition of PEG and NaCl. Wastewater samples were mixed, and a 1 mL
172 sample was reserved and stored at -80 °C. RNA was extracted as stated above.

173

174 **2.4. Detection and quantification of SARS-CoV-2**

175 A one-step RT-ddPCR approach was used to determine the copy number/20 µL of
176 SARS-CoV-2, and data were converted to copy number/100 mL wastewater for N1 and
177 N2 targets using the method published by Flood et al., 2001 (53). All the primers and
178 probes used in this study were published previously (13). Droplet digital PCR was
179 performed using Bio-Rad's 1-Step RT-ddPCR Advanced kit with a QX200 ddPCR
180 system (Bio-Rad, CA, USA). Each reaction contained a final concentration of
181 1× Supermix (Bio-Rad, CA, USA), 20 U µL⁻¹ reverse transcriptase (RT) (Bio-Rad,
182 CA, USA), 15 mM DTT, 900 nmol l⁻¹ of each primer, 250 nmol l⁻¹ of each probe, 1 µL of
183 molecular grade RNase-free water, and 5.5 µL of template RNA for a final reaction
184 volume of 22 µL (13, 53-55). RT was omitted for DNA targets. Droplet generation was
185 performed by microfluidic mixing of 20 µL of each reaction mixture with 70 µL of
186 droplet generation oil in a droplet generator (Bio-Rad, CA, USA) resulting in a final

187 volume of 40 μL of reaction mixture-oil emulsions containing up to 20,000 droplets with
188 a minimum droplet count of >9000 . The resulting droplets were then transferred to a
189 96-well PCR plate that was heat-sealed with foil and placed into a C1000 96-deep-well
190 thermocycler (Bio-Rad, CA, USA) for PCR amplification using the following
191 parameters: 25 $^{\circ}\text{C}$ for 3 min, 50 $^{\circ}\text{C}$ for 1 h, 95 $^{\circ}\text{C}$ for 10 min, followed by 40 cycles of 95
192 $^{\circ}\text{C}$ for 30 s and 60 $^{\circ}\text{C}$ for 1 min with ramp rate of 2 $^{\circ}\text{C}/\text{s}$ 1 followed by a final cycle of 98
193 $^{\circ}\text{C}$ for 10 min. Following PCR thermocycling, each 96-well plate was transferred to a
194 QX200 Droplet Reader (Bio-Rad, CA, USA) for the concentration determination through
195 the detection of positive droplets containing each gene target by spectrophotometric
196 detection of the fluorescent probe signal. All analyses were run in triplicate for each
197 marker. To derive recovery efficiencies for each sample site, Phi6-spiked pre- and post-
198 PEG concentration RNA samples were used to quantify Phi6 copy number using the
199 previously published primers and probes (13). The degree of PCR inhibition was also
200 quantified in each sample by spiking 10 μL of 10^5 GC/ml Phi6 in a sample's Buffer
201 AVL, including positive controls that lacked wastewater.

202

203 **2.5. Data analysis**

204 All SARS-CoV-2 gene data were converted from GC per 20 μL reaction to GC
205 per 100 mL wastewater sample before analysis (13, 53). Non-detects (ND) were assigned
206 their individual sample's limit of detection for the purposes of data reporting, although
207 any weekly on-campus or off-campus samples whose values matched the theoretical limit
208 of detection were removed prior to statistical analysis. The limit of detection was
209 calculated for each individual sample based on both the molecular assays' theoretical

210 detection limits (i.e., 3 positive droplets for RT-ddPCR; the lowest standard curve
211 concentration for RT-qPCR) and the concentration factor of each processing method
212 examined. All wastewater data were reported to MDHHS and uploaded to the Michigan
213 COVID-19 Sentinel Wastewater Epidemiological Evaluation Project (SWEEP)
214 dashboard ([https://www.michigan.gov/coronavirus/stats/wastewater-
215 surveillance/dashboard/sentinel-wastewater-epidemiology-evaluation-project-sweep](https://www.michigan.gov/coronavirus/stats/wastewater-surveillance/dashboard/sentinel-wastewater-epidemiology-evaluation-project-sweep)).

216

217 **2.6. Sequencing**

218 RNA was shipped to GT Molecular (Fort Collins, CO) on dry ice. Library
219 preparation was done using GT Molecular's proprietary method, which utilized ARTIC
220 4.1 primers for SARS-CoV-2 amplicon generation (<https://artic.network/ncov-2019>).
221 Amplicons were pooled and sequenced on a Miseq using 2x150bp reads. FASTQ files
222 were analyzed using GT Molecular's bioinformatics pipeline, and variant-calling was
223 performed using a modified and proprietary version of Freyja (56). FASTQ files for each
224 sample listed are available in the NCBI SRA database (Submission ID: SUB13897431;
225 BioProject ID: PRJNA1027333) (15).

226

227 **2.7. Complete reconstruction and identification of novel mutations**

228 FASTQ files from 10-26-21 (SAMN37791375), 11-9-21
229 (SAMN37791376), 9-12-22 (SAMN37791379), 3-13-23 (SAMN37791380), 4-24-23
230 (SAMN37791382), and 5-1-23 (SAMN37791383) contained reads that spanned each
231 SARS-CoV-2 open reading frame (ORF), they lacked contamination with other variants
232 of concern based on variant calling, and they had high relative abundance of the Alpha

233 variant lineage B.1.1.7 derivative (Table 1) (15). This allowed for reconstruction of
234 consensus genes for each of the above wastewater samples. Specifically, we uploaded
235 FASTA-formatted .txt files into Galaxy (<https://usegalaxy.org/>) that represented each
236 reference gene. Reference genes were constructed from an early consensus Alpha variant
237 lineage B.1.1.7 Michigan clinical isolate submitted on 1-26-21 (GenBank: MW525061.1;
238 Accession: MW525061). We then uploaded each of the paired-end FASTQ files for each
239 wastewater sample. The Bowtie2 program was used to map reads against each reference
240 sequence, creating individual .bam files per sample. The default setting was used for
241 analysis. The Convert Bam program was then used to convert .bam files to FASTA
242 multiple sequence alignments. Multiple sequence alignment files were uploaded to
243 MEGA (<https://www.megasoftware.net/>) and converted to amino acid sequence. The
244 consensus amino acid sequence from each of these samples was manually reconstructed
245 and then aligned with the reference gene. Mutations that were present in wastewater
246 samples but not the reference clinical sample were characterized as novel mutations. The
247 total number of reads that aligned to each reference gene were determined in MEGA and
248 FastQC was used to quantify read length and the number of poor-quality sequences
249 (Supplementary Table 1). At least 3 reads were present for each amino acid.

250

251 **2.8. Novel mutation hotspot analyses**

252 We identified novel mutations as described above. We then tracked the percent
253 prevalence of novel mutations in wastewater samples that were positive for the Alpha
254 variant lineage. Specifically, we uploaded FASTA-formatted .txt files into Galaxy
255 (<https://usegalaxy.org/>) that represented the SARS-CoV-2 reference genes. We then

256 uploaded each of the paired-end FASTQ files for each wastewater sample. The Bowtie2
257 program was used to map reads against the reference sequence. The default setting was
258 used for analysis. The Convert Bam program was then used to convert .bam files to
259 FASTA multiple sequence alignments. Multiple sequence alignment files were uploaded
260 to MEGA (<https://www.megasoftware.net/>) and converted to amino acid sequence for
261 open-reading frame analysis. Novel mutations were identified manually, and the column
262 of reads were copied and pasted into Excel. The column was selected, and the Analyze
263 Data tool was selected to calculate the percent prevalence of the novel mutations. This
264 was repeated for each novel mutation across all samples positive for Alpha variant
265 lineage and the percent prevalence data was represented in a heatmap. Novel mutations
266 were mapped onto 2-D representations of proteins and the 3-D protein structures when
267 available using UCSF Chimera (57).

268

269 **3. Results**

270 **3.1 Chronic shedding of an Alpha variant lineage at a rural WWTP.**

271 Wastewater samples were collected between July 2021 and June 2023 and SARS-
272 CoV-2 genome copies per 100 mL wastewater were determined each week and reported
273 to MDHHS (13, 15). One site was notable for higher peaks of virus shedding, which
274 culminated in a peak that was 4 logs higher than the mean for all sites, although high
275 peaks of activity were observed since 9-21-21 (15). In order to identify the SARS-CoV-2
276 variant responsible for this activity, RNA extracted from stored wastewater concentrates
277 was shipped to GT Molecular (Fort Collins, CO) and a next generation sequencing (NGS)
278 and variant calling pipeline was employed. RNA from the site of interest and neighboring

279 sites were analyzed as a control. The site of interest contained high relative abundance of
280 Delta variant lineage AY.25.1 at the first time point tested (i.e., 9-21-21) (15). This
281 corresponded to the beginning of the Delta variant wave in Central Michigan (13). The
282 site of interest began shedding the Alpha variant lineage during the next two time points
283 tested (10-26-21 and 11-9-21) (15). This was preceded by sequencing data from clinical
284 samples, which revealed 16 Alpha variant lineage Q.3 isolates collected from 2-18-21 to
285 7-9-21 (15). The site of interest had high relative abundance of Omicron variant lineages
286 during the next two time points tested (i.e., 3-14-22 and 4-25-22) (15). This corresponded
287 to the end of the first Omicron wave in Central Michigan (13). The Alpha variant lineage
288 became the dominant isolate in all remaining wastewater samples from the site of interest
289 in all 2022 and 2023 samples tested, with relative abundance ranging from 47.1-98.0%
290 (15). Specifically, for the samples analyzed in the current manuscript (i.e., 10-26-2021,
291 11-9-2021, 9-12-2022, 3-13-23, 4-24-23, and 5-1-23), the alpha variant represented 94.2-
292 98% of amplicons. Based on this information, it was possible to reconstruct alpha variant
293 genomes without significant contamination with other variants (Supplementary Figure 1).
294 Other sites contained Omicron variant lineages BG.5, XBB.1.5, XBB.1.5.23, XBB.1.28,
295 XBB.1.5.1, XBB.1.5.17, XBB.1.5.49, and Delta variant lineage DT.2 at varying relative
296 abundance during the same sampling period (15).

297

298 **3.2. Accumulation of novel mutations.**

299 We reasoned that chronic shedding of SARS-CoV-2 would lead to accumulation
300 of novel mutations that do not align with sequences identified in most clinical and
301 wastewater samples, which mostly result from acute infection. This hypothesis was

302 supported by our previous analysis of Spike, which identified 37 novel mutations that
303 accumulated during this time frame (15). Alignment of reconstructed consensus genes
304 with a reference Alpha variant lineage clinical sequence revealed that non-Spike proteins
305 had 35 novel mutations in the 5-1-2023 sample including mutations in nsp1 (1), nsp2 (1),
306 nsp3 (8), nsp4 (4), nsp5/3CLpro (2), nsp6 (2), RdRp (2), nsp15 (2), nsp16 (1), ORF3a
307 (4), M (2), ORF6 (1), ORF7a (1), ORF7b (1), and N (3) (Fig. 1). Each mutation was
308 analyzed using the NCBI Virus SARS-CoV-2 Variant Overview “Search GenBank +
309 SRA Data by Mutation” tool. This analysis identified the total records for each mutation
310 in GenBank and SRA databases during the time frame of Dec 2023 to Jun 2024.
311 Importantly, this time frame was 7 to 13 months after the last wastewater sample was
312 acquired. Very few records were identified for each of these mutations and some
313 mutations lacked records altogether (Table 2). We expanded the mutational analysis by
314 quantifying the percent prevalence of each of the 35 novel mutations identified in the 5-1-
315 2023 sample across all wastewater samples that were positive for the Alpha variant
316 lineage. A heatmap showed that these mutations accumulated and became dominant
317 within the population over time, while also retaining diversity at each position (Fig. 2).

318

319 **3.3. Nsp1**

320 One novel mutation accumulated in nsp1: S17I. S17I resides in the N-terminal domain
321 (NTD) (Figure 3A). It was found in 1 online record (Table 2). The impact of this
322 mutation on protein function and immune evasion is unknown.

323

324 **3.4. Nsp2**

325 One novel mutation accumulated in nsp2: G445C (G265C). ORF1ab mutations outside of
326 parentheses were determined from the first amino acid in nsp1. ORF1ab mutations inside
327 of parentheses were determined from the first amino acid of each protein. Both variations
328 were searched in the literature. G445C (G265C) was reported in India and found in a total
329 of 26 online records (Table 2) (21). The impact of this mutation on protein function and
330 immune evasion is unknown.

331

332 **3.5. Nsp3**

333 Eight novel mutations accumulated in nsp3: S944L (S126L), D1184E (D366E), A1306S
334 (A488S), H1545Y (H727Y), K1795Q (K977Q), R2115I (R1297I), H2520N (H1702N),
335 and S2661F (S1843F). S944L (S126L) resides in the hypervariable region (HVR),
336 D1184E (D366E) resides in macrodomain II (Mac2), A1306S (A488S) resides in
337 macrodomain III (Mac3), H1545Y (H727Y) resides in the ubiquitin-like domain 2
338 (Ubl2), K1795Q (K977Q) resides in the PL2^{pro} domain, R2115I (R1297I) resides within
339 the betacoronavirus-specific marker (β SM), and H2520N (H1702N) and S2661F
340 (S1843F) reside in the Y1 and CoV-Y domains (Figure 3C). S944L (S126L), A1306S
341 (A488S), and S2661F (S1843F) were reported in Asian isolates and found in a total of
342 208, 0, and 42 online records, respectively (Table 2) (22-25). H1545Y (H727Y) was
343 reported in Italy and found in a total of 5 online records (Table 2) (26). K1795Q (K977Q)
344 was reported in Brazil, was present at a higher frequency in immunodeficient patients,
345 and found in a total of 13 online records (Table 2) (27, 28). R2115I (R1297I) was
346 reported in Moldova and found in a total of 14 online records (29). D1184E (D366E) and
347 H2520N (H1702N) have not been previously reported and were found in a total of 14 and

348 0 online records, respectively. The impact of these mutations on nsp3 protein function
349 and immune evasion is unknown.

350

351 **3.6. Nsp4**

352 Four novel mutations accumulated in nsp4: M2796I (M33I), V2943F (V180F), I2961F
353 (I198F), and D2980G (D217G). M2796I (M33I) resides in a transmembrane domain
354 (TD), and V2943F (V180F), I2961F (I198F), and D2980G (D217G) reside in the luminal
355 domain (LD) (Figure 3D). M2796I (M33I) was reported in the Middle East and
356 computational analysis suggested that the mutation causes secondary structure changes
357 converting an alpha helix to a beta sheet, which may impact interaction between nsp3 and
358 nsp4 (30, 31). D2980G (D217G) and M2796I (M33I) were reported in Asian isolates and
359 were found in a total of 21 and 72 online records, respectively (32, 33). V2943F (V180F)
360 and I2961F (I198F) have not been previously reported and were found in a total of 3 and
361 0 online records, respectively. The impact of these mutations on protein function and
362 immune evasion are unknown.

363

364 **3.7. Nsp5/3CLpro**

365 Two novel mutations accumulated in nsp5: R3353K (R90K) and K3499R (K236R).
366 R3353K (R90K) resides in domain 1 (D1) and K3499R (K236R) resides in D3 (Figure
367 3E). R3353K (R90K) was not previously reported and was found in 0 online records
368 (Table 2). K3499R (K236R) was reported in Indian isolates and was found in a total of 5
369 online records (Table 2) (32). The impact of these mutations on protein function and
370 immune evasion are unknown.

371

372 **3.8. Nsp6**

373 Two novel mutations accumulated in nsp6: L3606F (L37F) and F3750V (F184V).
374 L3606F (L37F) resides in a transmembrane domain (TD) and F3750V (F184V) resides in
375 a luminal domain (LD) (Figure 3F). L3606F (L37F) was reported in Asian isolates and
376 was found in a total of 1,698 (2%) online records (Table 2) (34). Previous research found
377 that L3606F (L37F) reduced nsp6's interaction with ATP6AP1. This allowed for
378 lysosomal acidification to proceed normally, which prevented activation of the NLRP3
379 inflammasome pathway. The investigators noted that this mutation reduced SARS-CoV-2
380 fitness, and that this may be why the mutation is not present in circulating variants of
381 concern (35, 36). F3750V (F184V) was reported in a basic science study as an adaptive
382 mutation that arose in ferrets and *in vitro* during treatment with remdesivir (16, 17). This
383 mutation was not reported in clinical sequences but was present in a total of 8 online
384 records (Table 2).

385

386 **3.9. RdRp**

387 Two novel mutations accumulated in RdRp: S4618N (S229N) and T5301N (T912N).
388 S4618N (S229N) resides in the NTD and T5301N (T912N) resides in the thumb domain
389 (TD) (Figure 3G). S4618N (S229N) was not previously reported and was present in a
390 total of 42 online records (Table 2). T5301N (T912N) was reported in Italy and was
391 present in a total of 0 online records (Table 2) (37). The impact of these mutations on
392 protein function and immune evasion are unknown.

393

394 **3.10. Nsp15**

395 Two novel mutations accumulated in nsp15: E6709K (E260K) and F6712L (F263L).
396 Both E6709K (E260K) and F6712L (F263L) reside in the nuclease EndoU domain
397 (Figure 3H). E6709K (E260K) was reported in Italy and was present in a total of 4 online
398 records (Table 2). This mutation was associated with an increased frequency of mortality
399 (38). F6712L (F263L) was not previously reported and was present in a total of 14 online
400 records (Table 2). The impact of these mutations on protein function and immune evasion
401 are unknown.

402

403 **3.11. Nsp16**

404 One novel mutation accumulated in nsp16: R7011N (R216N). R7011N (R216N) was
405 reported in Brazil and was present in a total of 0 online records (Table 2). This mutation
406 was associated with reinfection of a healthcare worker (19). The impact of this mutation
407 on protein function and immune evasion is unknown.

408

409 **3.12. ORF3a**

410 Four novel mutations accumulated in ORF3a: I35K, E102D, G172R, and M260K. I35K
411 resides in the N-terminal domain (NTD), E102D resides in the transmembrane domain
412 (TD), and both G172R and M260K reside in the C-terminal domain (CTD) (Figure 4A).
413 I35K and E102D have not been previously reported. G172R and M260K were previously
414 reported in variants of concern (39-42). The impact of these mutations on ORF3a protein
415 function and immune evasion is unknown.

416

417 **3.13. M**

418 Two novel mutations accumulated in M: D3N and Q19H. Both mutations reside in the N-
419 terminal domain (NTD), which are surface exposed (Figure 4B). D3N was previously
420 identified in BA.5 strains and may result in N-myristoylation possibly impacting
421 membrane integrity, post-translational modification, and immune evasion (43, 44). Q19H
422 has not been previously reported but based on its location it may have similar functional
423 consequences as D3N.

424

425 **3.14. ORF6**

426 One novel mutation accumulated in ORF6: D61E. This is the last residue in the open
427 reading frame. D61E has not been previously reported. The impact of this mutation on
428 ORF6 protein function and immune evasion is unknown.

429

430 **3.15. ORF7a**

431 One novel mutation accumulated in ORF7a: T120I. This is the second to last C-terminal
432 residue and resides in the endoplasmic reticulum retention sequence (Figure 4D). T120I
433 has been previously identified in variants of concern (45). The impact of this mutation on
434 ORF7a protein function and immune evasion is unknown.

435

436 **3.16. ORF7b**

437 One novel mutation accumulated in ORF7b: A43V. This is the last residue in the C-
438 terminal domain (Figure 4E). A43V has not been previously reported. The impact of this
439 mutation on ORF7b protein function and immune evasion is unknown.

440

441 **3.17. N**

442 Three novel mutations accumulated in the N gene: N8D, S37P, and F235S. N8D resides
443 in the N-terminal domain (NTD) and both S37P and F235S reside in the linker sequence
444 between the known functional domains (Figure 4F). N8D was previously identified in
445 B.1.1.7 strains (46, 47). S37P was previously identified in SARS-CoV-2 isolates (48, 49).
446 F235S has not been previously reported. The impact of these mutations on N protein
447 function and immune evasion is unknown.

448

449 **4. Discussion**

450 Retrospective analysis of wastewater data revealed that one rural site produced
451 consistently higher concentrations of SARS-CoV-2 copy numbers. NGS sequencing
452 revealed that this site began shedding an Alpha variant lineage by October 2021 and that
453 this continued to at least May 2023. Clinical sequence data revealed that Alpha variant
454 lineage Q.3/Q.4 was present in Michigan between February to July 2021. This preceded
455 the start of wastewater surveillance in central Michigan and our first detection of the
456 Alpha variant lineage in wastewater by 3-8 months. It is unclear how many individuals
457 were originally infected with this lineage at the site of interest, and it is unclear how
458 many individuals continued to shed the virus into the sewer shed. However, due to the
459 small population served at this rural WWTP, our October 2021 Alpha variant lineage
460 reconstruction likely represents a chronic infection that lasted for 2-7 months. At this
461 stage of the chronic infection, the Alpha variant lineage already accumulated 9 novel

462 mutations in the Spike gene and 10 novel mutations spread across nsp1, nsp3, nsp5, nsp6,
463 nsp15, nsp16, and N (15).

464

465 Eighteen months later, the Alpha variant lineage shed from this site had 72 novel
466 non-structural (nsp1, nsp2, nsp3, nsp4, nsp5/3CLpro, nsp6, RdRp, nsp15, nsp16, ORF3a,
467 ORF6, ORF7a, and ORF7b) and structural (Spike, M, and N) mutations (15). Spike
468 mutations present in these wastewater samples have been described previously. Many of
469 the Spike mutations were associated with experimental evidence suggesting they
470 promoted immune evasion, and three mutations were previously found in
471 immunocompromised patients (15). Similarly, nsp3 K1795Q (K977Q) was present at a
472 higher frequency in immunodeficient patients, nsp6 F3750V (F184V) was an adaptive
473 mutation that accumulated in the presence of remdesivir *in vitro* and *in vivo*, and nsp16
474 R7011N (R216N) was present in a reinfected healthcare worker (16, 17, 19, 28).
475 Considering that 8% of the novel mutations in Spike and non-Spike genes were
476 associated with known persistent infections, we can assume that many of the identified
477 mutations are selected during chronic infection.

478

479 Without experimental evidence, it is impossible to know the precise role of each
480 mutation during chronic infection, although we can infer based on known structural and
481 functional information for each protein, in addition to serological data in the human host.
482 For instance, the two mutations present in M protein (D3N and Q19H) reside in the N-
483 terminal domain (NTD) and are surface exposed (50, 51). Previous research has
484 identified D3N in BA.5 strains and investigators suggested that the mutation may result

485 in N-myristoylation possibly impacting membrane integrity, post-translational
486 modification, and immune evasion (43, 44). Similar to Spike, antibodies directed to M
487 are generated during infection, persist for at least a year after infection, and generate a
488 similar level of reactivity as immunodominant linear epitopes (50-52). It's possible that
489 during a chronic infection SARS-CoV-2 optimizes Spike and M to evade adaptive
490 immunity.

491

492 These data provide evidence that, while rare, an individual can be chronically
493 infected with SARS-CoV-2 over many months and possibly a few years. It is possible
494 that multiple individuals contributed to the persistence of this variant of concern. During
495 this time, SARS-CoV-2 can accumulate many mutations in Spike and non-Spike genes.
496 Some of these mutations have been found in persistent infections. Further research is
497 needed to determine which of these mutations are predictive of chronic infection and if
498 they can be used as a biomarker in individuals with persistent disease and leveraged to
499 tailor selection or development of pharmaceutical therapies. This study also shows that
500 small WWTPs can enhance the resolution of rare biological events and allow for total
501 reconstruction of viral genomes and their corresponding proteins.

502

503 **Figure legends**

504

505 **Figure 1. SARS-CoV-2 genome map with novel mutations identified as red dashes**
506 **under each open reading frame (ORF): nsp1 (1), nsp2 (1), nsp3 (8), nsp4 (4),**

507 **nsp5/3CLpro (2), nsp6 (2), RdRp (2), nsp15 (2), nsp16 (1), S (37), ORF3a (4), M (2),**
508 **ORF6 (1), ORF7a (1), ORF7b (1), and N (3).**

509

510 **Figure 2. Heatmap showing the percent prevalence of novel non-Spike mutations in**
511 **each wastewater sample that was positive for the Alpha variant lineage. ORF1ab**
512 **mutations outside of parentheses were determined from the first amino acid in nsp1.**
513 **ORF1ab mutations inside of parentheses were determined from the first amino acid**
514 **of each protein.**

515

516 **Figure 3. Novel mutations present in ORF1ab genes were mapped onto 2-D and 3-D**
517 **protein models: (A) nsp1, (B) nsp2, (C) nsp3, (D) nsp4, (E) nsp5/3CLpro, (F) nsp6,**
518 **(G) RdRp, (H) nsp15, and (I) nsp16. Structures were rendered using UCSF Chimera**
519 **and RCSB PDB numbers were provided (58). Individual protein domains were**
520 **indicated in blue and multimers/other molecules were indicated as gray. Mutations**
521 **were highlighted and noted in red.**

522

523 **Figure 4. Novel mutations present in ORF genes were mapped onto 2-D and 3-D**
524 **protein models. (A) ORF3a, (B) M, (C) ORF6, (D) ORF7a, (E) ORF7b, and (F) N.**
525 **Structures were rendered using UCSF Chimera and RCSB PDB numbers were**
526 **provided (58). Individual protein domains were indicated in blue and**
527 **multimers/other molecules were indicated as gray. Mutations were highlighted and**
528 **noted in red.**

529

530 **Supplementary Figure 1. Reconstructed ORFs in FASTA format**

531 **Supplementary Table 1. Total RNA-Seq reads present for each SARS-CoV-2 ORF**

532


533 **References**


- 534 1. Anderson-Coughlin BL, Shearer AEH, Omar AN, Litt PK, Bernberg E, Murphy
535 M, et al. Coordination of SARS-CoV-2 wastewater and clinical testing of university
536 students demonstrates the importance of sampling duration and collection time. *Sci Total*
537 *Environ.* 2022;830:154619.
- 538 2. Betancourt WQ, Schmitz BW, Innes GK, Prasek SM, Pogreba Brown KM, Stark
539 ER, et al. COVID-19 containment on a college campus via wastewater-based
540 epidemiology, targeted clinical testing and an intervention. *Sci Total Environ.*
541 2021;779:146408.
- 542 3. Corchis-Scott R, Geng Q, Seth R, Ray R, Beg M, Biswas N, et al. Averting an
543 Outbreak of SARS-CoV-2 in a University Residence Hall through Wastewater
544 Surveillance. *Microbiol Spectr.* 2021;9(2):e0079221.
- 545 4. Gibas C, Lambirth K, Mittal N, Juel MAI, Barua VB, Roppolo Brazell L, et al.
546 Implementing building-level SARS-CoV-2 wastewater surveillance on a university
547 campus. *Sci Total Environ.* 2021;782:146749.
- 548 5. Jarvie M, M., Reed M, Southwell B, Wright D, Nguyen T, Ngoc, Thi. RT-ddPCR
549 Wastewater Monitoring of COVID-19 Across the Eastern Upper Peninsula of Michigan.
550 SSRN2022.
- 551 6. Scott LC, Aubee A, Babahaji L, Vigil K, Tims S, Aw TG. Targeted wastewater
552 surveillance of SARS-CoV-2 on a university campus for COVID-19 outbreak detection
553 and mitigation. *Environ Res.* 2021;200:111374.
- 554 7. Wong TE, Thurston GM, Barlow N, Cahill ND, Carichino L, Maki K, et al.
555 Evaluating the sensitivity of SARS-CoV-2 infection rates on college campuses to
556 wastewater surveillance. *Infect Dis Model.* 2021;6:1144-58.
- 557 8. Rondeau NC, Rose OJ, Alt ER, Ariyan LA, Elikan AB, Everard JL, et al.
558 Building-Level Detection Threshold of SARS-CoV-2 in Wastewater. *Microbiol Spectr.*
559 2023:e0292922.
- 560 9. Chua FJD, Kim SY, Hill E, Cai JW, Lee WL, Gu X, et al. Co-incidence of BA.1
561 and BA.2 at the start of Singapore's Omicron wave revealed by Community and
562 University Campus wastewater surveillance. *Sci Total Environ.* 2023;875:162611.
- 563 10. Vo V, Tillett RL, Papp K, Chang CL, Harrington A, Moshi M, et al. Detection of
564 the Omicron BA.1 Variant of SARS-CoV-2 in Wastewater From a Las Vegas Tourist
565 Area. *JAMA Netw Open.* 2023;6(2):e230550.
- 566 11. Pico-Tomás A, Mejías-Molina C, Zammit I, Rusiñol M, Bofill-Mas S, Borrego
567 CM, et al. Surveillance of SARS-CoV-2 in sewage from buildings housing residents with
568 different vulnerability levels. *Sci Total Environ.* 2023;872:162116.
- 569 12. Lehto KM, Länsivaara A, Hyder R, Luomala O, Lipponen A, Hokajärvi AM, et
570 al. Wastewater-based surveillance is an efficient monitoring tool for tracking influenza A
571 in the community. *Water Res.* 2024;257:121650.


- 572 13. Conway MJ, Kado S, Kooienga BK, Sarette JS, Kirby MH, Marten AD, et al.
573 SARS-CoV-2 wastewater monitoring in rural and small metropolitan communities in
574 Central Michigan. *Sci Total Environ.* 2023;894:165013.
- 575 14. Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A, et
576 al. Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-
577 January 12, 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70(3):95-9.
- 578 15. Conway MJ, Yang H, Revord LA, Novay MP, Lee RJ, Ward AS, et al. Chronic
579 shedding of a SARS-CoV-2 Alpha variant in wastewater. *BMC Genomics.*
580 2024;25(1):59.
- 581 16. Checkmahomed L, Carbonneau J, Du Pont V, Riola NC, Perry JK, Li J, et al. In
582 Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to
583 Resistance. *Antimicrob Agents Chemother.* 2022;66(7):e0019822.
- 584 17. Cox RM, Wolf JD, Lieber CM, Sourimant J, Lin MJ, Babusis D, et al. Oral
585 prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets.
586 *Nat Commun.* 2021;12(1):6415.
- 587 18. Kemp SA, Collier DA, Datir RP, Ferreira I, Gayed S, Jahun A, et al. SARS-CoV-
588 2 evolution during treatment of chronic infection. *Nature.* 2021;592(7853):277-82.
- 589 19. Camargo CH, Gonçalves CR, Pagnoca E, Campos KR, Montanha JOM, Flores
590 MNP, et al. SARS-CoV-2 reinfection in a healthcare professional in inner Sao Paulo
591 during the first wave of COVID-19 in Brazil. *Diagn Microbiol Infect Dis.*
592 2021;101(4):115516.
- 593 20. Ahmadi AS, Zadheidar S, Sadeghi K, Nejati A, Salimi V, Hajiabdolbaghi M, et
594 al. SARS-CoV-2 intrahost evolution in immunocompromised patients in comparison with
595 immunocompetent populations after treatment. *J Med Virol.* 2023;95(6):e28877.
- 596 21. Sarkar R, Saha R, Mallick P, Sharma R, Kaur A, Dutta S, et al. Emergence of a
597 novel SARS-CoV-2 Pango lineage B.1.1.526 in West Bengal, India. *J Infect Public*
598 *Health.* 2022;15(1):42-50.
- 599 22. Shah A, Rehmat S, Aslam I, Suleman M, Batool F, Aziz A, et al. Comparative
600 mutational analysis of SARS-CoV-2 isolates from Pakistan and structural-functional
601 implications using computational modelling and simulation approaches. *Comput Biol*
602 *Med.* 2022;141:105170.
- 603 23. Abdullaev A, Abdurakhimov A, Mirakbarova Z, Ibragimova S, Tsoy V,
604 Nuriddinov S, et al. Genome sequence diversity of SARS-CoV-2 obtained from clinical
605 samples in Uzbekistan. *PLoS One.* 2022;17(6):e0270314.
- 606 24. Zhu M, Zeng Q, Saputro BIL, Chew SP, Chew I, Frendy H, et al. Tracking the
607 molecular evolution and transmission patterns of SARS-CoV-2 lineage B.1.466.2 in
608 Indonesia based on genomic surveillance data. *Virol J.* 2022;19(1):103.
- 609 25. Laskar R, Ali S. Mutational analysis and assessment of its impact on proteins of
610 SARS-CoV-2 genomes from India. *Gene.* 2021;778:145470.
- 611 26. De Marco C, Marascio N, Veneziano C, Biamonte F, Trecarichi EM, Santamaria
612 G, et al. Whole-genome analysis of SARS-CoV-2 in a 2020 infection cluster in a nursing
613 home of Southern Italy. *Infect Genet Evol.* 2022;99:105253.
- 614 27. Ramesh S, Govindarajulu M, Parise RS, Neel L, Shankar T, Patel S, et al.
615 Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and
616 Vaccine Efficacy. *Vaccines (Basel).* 2021;9(10).

- 617 28. Wilkinson SAJ, Richter A, Casey A, Osman H, Mirza JD, Stockton J, et al.
618 Recurrent SARS-CoV-2 mutations in immunodeficient patients. *Virus Evol.*
619 2022;8(2):veac050.
- 620 29. Ulinici M, Soñora M, Orsini E, Licastro D, Dal Monego S, Todiras M, et al.
621 Genome Sequences of SARS-CoV-2 Strains from the Republic of Moldova. *Microbiol*
622 *Resour Announc.* 2023;12(1):e0113222.
- 623 30. Rehman S, Mahmood T, Aziz E, Batool R. Identification of novel mutations in
624 SARS-COV-2 isolates from Turkey. *Arch Virol.* 2020;165(12):2937-44.
- 625 31. Abou-Hamdan M, Hamze K, Abdel Sater A, Akl H, El-Zein N, Dandache I, et al.
626 Variant analysis of the first Lebanese SARS-CoV-2 isolates. *Genomics.* 2021;113(1 Pt
627 2):892-5.
- 628 32. Das JK, Sengupta A, Choudhury PP, Roy S. Characterizing genomic variants and
629 mutations in SARS-CoV-2 proteins from Indian isolates. *Gene Rep.* 2021;25:101044.
- 630 33. Sassi MB, Ferjani S, Mkada I, Arbi M, Safer M, Elmoussi A, et al. Phylogenetic
631 and amino acid signature analysis of the SARS-CoV-2s lineages circulating in Tunisia.
632 *Infect Genet Evol.* 2022;102:105300.
- 633 34. Omotoso OE, Olugbami JO, Gbadegesin MA. Assessment of intercontinents
634 mutation hotspots and conserved domains within SARS-CoV-2 genome. *Infect Genet*
635 *Evol.* 2021;96:105097.
- 636 35. Bills C, Xie X, Shi PY. The multiple roles of nsp6 in the molecular pathogenesis
637 of SARS-CoV-2. *Antiviral Res.* 2023;213:105590.
- 638 36. Sun X, Liu Y, Huang Z, Xu W, Hu W, Yi L, et al. SARS-CoV-2 non-structural
639 protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1. *Cell Death*
640 *Differ.* 2022;29(6):1240-54.
- 641 37. Equestre M, Marcantonio C, Marascio N, Centofanti F, Martina A, Simeoni M, et
642 al. Characterization of SARS-CoV-2 Variants in Military and Civilian Personnel of an
643 Air Force Airport during Three Pandemic Waves in Italy. *Microorganisms.* 2023;11(11).
- 644 38. Fang S, Liu S, Shen J, Lu AZ, Wang AKY, Zhang Y, et al. Updated SARS-CoV-
645 2 single nucleotide variants and mortality association. *J Med Virol.* 2021;93(12):6525-34.
- 646 39. Tierling S, Kattler K, Vogelgesang M, Pfuhl T, Lohse S, Lo Porto C, et al. Rapid
647 Base-Specific Calling of SARS-CoV-2 Variants of Concern Using Combined RT-PCR
648 Melting Curve Screening and SIRPH Technology. *Open Forum Infect Dis.*
649 2021;8(8):ofab364.
- 650 40. Patro LPP, Sathyaseelan C, Uttamrao PP, Rathinavelan T. The evolving proteome
651 of SARS-CoV-2 predominantly uses mutation combination strategy for survival. *Comput*
652 *Struct Biotechnol J.* 2021;19:3864-75.
- 653 41. Azad GK, Khan PK. Variations in Orf3a protein of SARS-CoV-2 alter its
654 structure and function. *Biochem Biophys Rep.* 2021;26:100933.
- 655 42. Franceschi VB, Caldana GD, Perin C, Horn A, Peter C, Cybis GB, et al.
656 Predominance of the SARS-CoV-2 Lineage P.1 and Its Sublineage P.1.2 in Patients from
657 the Metropolitan Region of Porto Alegre, Southern Brazil in March 2021. *Pathogens.*
658 2021;10(8).
- 659 43. Hossain A, Akter S, Rashid AA, Khair S, Alam A. Unique mutations in SARS-
660 CoV-2 Omicron subvariants' non-spike proteins: Potential impacts on viral pathogenesis
661 and host immune evasion. *Microb Pathog.* 2022;170:105699.

- 662 44. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, et al.
663 Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. *Nat Med.*
664 2022;28(9):1785-90.
- 665 45. Cruz CAK, Medina PMB. Temporal changes in the accessory protein mutations
666 of SARS-CoV-2 variants and their predicted structural and functional effects. *J Med*
667 *Viol.* 2022;94(11):5189-200.
- 668 46. Zárate S, Taboada B, Muñoz-Medina JE, Iša P, Sanchez-Flores A, Boukadida C,
669 et al. The Alpha Variant (B.1.1.7) of SARS-CoV-2 Failed to Become Dominant in
670 Mexico. *Microbiol Spectr.* 2022;10(2):e0224021.
- 671 47. Dimonte S, Babakir-Mina M, Hama-Soor T, Ali S. Genetic Variation and
672 Evolution of the 2019 Novel Coronavirus. *Public Health Genomics.* 2021;24(1-2):54-66.
- 673 48. Mohammad T, Choudhury A, Habib I, Asrani P, Mathur Y, Umair M, et al.
674 Genomic Variations in the Structural Proteins of SARS-CoV-2 and Their Deleterious
675 Impact on Pathogenesis: A Comparative Genomics Approach. *Front Cell Infect*
676 *Microbiol.* 2021;11:765039.
- 677 49. Timmers L, Peixoto JV, Ducati RG, Bachega JFR, de Mattos Pereira L, Caceres
678 RA, et al. SARS-CoV-2 mutations in Brazil: from genomics to putative clinical
679 conditions. *Sci Rep.* 2021;11(1):11998.
- 680 50. Williams DM, Hornsby HR, Shehata OM, Brown R, Gallis M, Meardon N, et al.
681 Establishing SARS-CoV-2 membrane protein-specific antibodies as a valuable
682 serological target via high-content microscopy. *iScience.* 2023;26(7):107056.
- 683 51. Jörrißen P, Schütz P, Weiland M, Vollenberg R, Schrempf IM, Ochs K, et al.
684 Antibody Response to SARS-CoV-2 Membrane Protein in Patients of the Acute and
685 Convalescent Phase of COVID-19. *Front Immunol.* 2021;12:679841.
- 686 52. Sullivan DJ, Franchini M, Joyner MJ, Casadevall A, Focosi D. Analysis of anti-
687 SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and
688 unvaccinated convalescent plasma sources. *Nat Commun.* 2022;13(1):6478.
- 689 53. Flood MT, D'Souza N, Rose JB, Aw TG. Methods Evaluation for Rapid
690 Concentration and Quantification of SARS-CoV-2 in Raw Wastewater Using Droplet
691 Digital and Quantitative RT-PCR. *Food Environ Virol.* 2021;13(3):303-15.
- 692 54. Lu X, Wang L, Sakthivel SK, Whitaker B, Murray J, Kamili S, et al. US CDC
693 Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory
694 Syndrome Coronavirus 2. *Emerg Infect Dis.* 2020;26(8):1654-65.
- 695 55. Lee HW, Lee HM, Yoon SR, Kim SH, Ha JH. Pretreatment with propidium
696 monoazide/sodium lauroyl sarcosinate improves discrimination of infectious waterborne
697 virus by RT-qPCR combined with magnetic separation. *Environ Pollut.* 2018;233:306-14.
- 698 56. Karthikeyan S, Levy JI, De Hoff P, Humphrey G, Birmingham A, Jepsen K, et al.
699 Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission. *Nature.*
700 2022;609(7925):101-8.
- 701 57. Wrobel AG, Benton DJ, Xu P, Roustan C, Martin SR, Rosenthal PB, et al. SARS-
702 CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and
703 furin-cleavage effects. *Nat Struct Mol Biol.* 2020;27(8):763-7.
- 704 58. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et
705 al. UCSF Chimera--a visualization system for exploratory research and analysis. *J*
706 *Comput Chem.* 2004;25(13):1605-12.
- 707










Table 1. GT Molecular Variant Calling

Location code	Sample date	VOC (%) ^a	Lineage(s) (%) ^b
VM	10-26-21	Alpha (94.2)	Q.3 (94.2)
VM	11-9-21	Alpha (94.9)	Q.4 (94.7)
VM	9-12-22	Alpha (97.3)	Q.4 (96.9)
VM	3-13-23	Alpha (98.0)	Q.4 (65.5)
VM	4-24-23	Alpha (97.9)	Q.4 (89.7)
VM	5-1-23	Alpha (97.4)	Q.4 (97.1)

a, Relative abundance of variants of concern (VOC) as a percentage

b, Relative abundance of VOC lineages as a percentage

Table 2. Total Records of Non-Spike Mutations Identified in a Chronic SARS-CoV-2 Alpha Variant

MUTATION	SRA	GenBank	Unique Samples
NSP1:S17I	1	0	1
NSP2:G445C (G265C) ^a	6	20	21
NSP3:S944L (S126L)	60	148	111
NSP3:D1184E (D366E)	6	8	6
NSP3:A1306S (A488S)	0	0	0
NSP3:H1545Y (H727Y)	1	4	2
NSP3:K1795Q (K977Q)	2	11	8
NSP3:R2115I (R1297I)	13	1	13
NSP3:H2520N (H1702N)	0	0	0
NSP3:S2661F (S1843F)	19	23	25
NSP4:M2796I (M33I)	33	39	41
NSP4:V2943F (V180F)	1	2	1
NSP4:I2961F (I198F)	0	0	0
NSP4:D2980G (D217G)	11	10	11
3CLpro:R3353K (R90K)	0	0	0
3CLpro:K3499R (K236R)	1	4	4
NSP6:L3606F (L37F)	714	984	977
NSP6:F3750V (F184V)	2	6	6
RdRp:S4618N (S229N)	13	29	18
RdRp:T5301N (T912N)	0	0	0
NSP15:E6709K (E260K)	2	2	2
NSP15:F6712L (F263L)	6	8	8
NSP16:R7011N (R216N)	0	0	0
ORF3a:I35K	42	56	46
ORF3a:E102D	1	2	2
ORF3a:G172R	0	1	0
ORF3a:M260K	11	17	15
M:D3N	13	14	19
M:Q19H	0	0	0
ORF6:D61E	0	0	0
ORF7a:T120I	34	72	63
ORF7b:A43V	43	68	65
N:N8D	2	3	2
N:S37P	28	48	48
N:F235S	0	0	0

^a *ORF1ab mutations outside of parentheses were determined from the first amino acid in nsp1. ORF1ab mutations inside of parentheses were determined from the first amino acid of each protein and were required for this analysis.*